🇺🇸 Bimatoprost Ophthalmic Solution in United States
37 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 37
Most-reported reactions
- Eye Irritation — 7 reports (18.92%)
- Ocular Hyperaemia — 7 reports (18.92%)
- Drug Ineffective — 5 reports (13.51%)
- Eye Pain — 4 reports (10.81%)
- Product Quality Issue — 3 reports (8.11%)
- Wrong Technique In Product Usage Process — 3 reports (8.11%)
- Drug Ineffective For Unapproved Indication — 2 reports (5.41%)
- No Adverse Event — 2 reports (5.41%)
- Off Label Use — 2 reports (5.41%)
- Product Substitution Issue — 2 reports (5.41%)
Other Ophthalmology approved in United States
Frequently asked questions
Is Bimatoprost Ophthalmic Solution approved in United States?
Bimatoprost Ophthalmic Solution does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Bimatoprost Ophthalmic Solution in United States?
Allergan is the originator. The local marketing authorisation holder may differ — check the official source linked above.